Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy. Biomol Biomed [Internet]. 2023 Dec. 1 [cited 2025 Apr. 17];24(4):688–697. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/9838